BioSpace News Archive

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, reported financial results for the quarter ended June 30, 2023.

LeMaitre, a provider of vascular devices, implants and services, reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, reported its second quarter 2023 financial results.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Nektar Therapeutics will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-based financial markets.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Ontario Drug Benefit Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Acadia Pharmaceuticals Inc. announced that on July 18, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of common stock and 11,988 restricted stock units to 16 new employees under Acadia’s 2023 Inducement Plan.

Tarsus Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 5,714,285 shares of its common stock at a public offering price of $17.50 per share, before underwriting discounts and commissions.